Are you treating extrapulmonary neuroendocrine carcinomas based on where they start—or what they actually are?

In this faculty follow-up to their i3 Health activity (Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets), Andrew Hendifar, MD, and Danielle Hutchings, MD (Cedars-Sinai Medical Center), unpack why treating these rare, aggressive tumors according to site of origin rather than tumor lineage can compromise outcomes. They clarify crucial pathologic distinctions between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) while emphasizing the essential role of multidisciplinary collaboration in precision care.

The experts also explore the novel therapeutic landscape of delta-like ligand 3 (DLL3)–targeted therapies, highlighting the promise of DLL3 T-cell engagers in extrapulmonary disease. They address ongoing diagnostic hurdles—such as standardized immunohistochemistry (IHC) expression thresholds and expanding send-out testing access—while sharing key insights on emerging clinical trials evaluating T-cell engager monotherapies and chemo-immunotherapy combinations.

Claim your CME credit: bit.ly/488fPhK

Download and review the companion Clinical Challenges in Extrapulmonary NEC Slide Deck: bit.ly/4w2Pni3

What if hitting prostate cancer earlier and harder is the key to delaying disease progression and sparing patients from invasive salvage therapies?

In this follow-up to his i3 Health Virtual Tumor Board, Stephen Freedland, MD, Cedars-Sinai Medical Center, unpacks practice-changing data from ASCO that is actively reshaping care algorithms across the prostate cancer continuum. Dr. Freedland dives into the breakthrough TALAPRO-3 trial—exploring why talazoparib plus enzalutamide is making waves across diverse HRR alterations (including BRCA and ATM)—and analyzes how the PROTEUS trial’s 35% reduction in subsequent salvage therapies could redefine surgical planning for high-risk localized disease. Plus, get an insider's look at what’s on the horizon with PSMA PET imaging, T-cell engagers, and AR degraders.

🎓Complete the Educational Activity: https://bit.ly/4x2BnWf

Chronic inflammatory demyelinating polyneuropathy (CIDP) presents significant challenges in both diagnosis and long-term disease management. As consensus definitions, emerging targeted therapies, and research into serologic biomarkers evolve, how can clinicians optimize individual care algorithms?

In this follow-up discussion, Karissa Gable, MD, Duke University Medical Center, breaks down recent breakthroughs in CIDP care and trial design:

- Standardizing CIDP Terminology: Key updates from the new international consensus definitions paper establishing unified criteria for disease remission, stability, treatment response, and refractory disease.

- The Emerging Pipeline: What’s next in therapeutic development, including FcRn antagonists (nipocalimab and batoclimab) and complement inhibitors.

- Shared Decision-Making: Practical strategies for tailoring therapy selection based on patient preferences, lifestyle, comorbidities, and administration routes.

- Building Confidence in CIDP Care: Applying 2021 EAN/PNS guidelines to navigate diagnosis and ongoing treatment adjustments when first-line options fall short.

💡 Complete the Educational Activity: https://bit.ly/4pPcVWe

👉 Access the accompanying slide deck for comprehensive guidance on CIDP detection and management: https://bit.ly/4pPcVWe

Read the full article here: https://oncdata.com/information-overload-and-the-portal-patient

The way that patients receive medical information has changed dramatically. Through electronic health record portals, laboratory values, imaging reports, and pathology results often become available the moment they are finalized—sometimes before a physician has had the opportunity to review or discuss them. While this unprecedented access promotes transparency and patient engagement, it also creates new challenges for communication, trust, and anxiety management. In the latest episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, to explore how instant access to test results is reshaping oncology care.

Read the full article here! https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging

As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Dr. Sean Raj, Chief Innovation Officer and Chief Medical Officer at SimonMed, about how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while empowering clinicians with new tools for preventive care.

Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient?

In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on:

🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles.

🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy.

🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients.

📅 Save Your Spot for the Live Event!

Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman.

Session 1: July 8 at 6:00 pm ET: bit.ly/3SitVaC

Session 2: July 28 at 7:00 pm ET: bit.ly/4oIAcZo

View the full article at: https://oncdata.com/oncology-unfiltered-tumor-board-vs-tuesday-afternoon

Tumor boards play a pivotal role in oncology care. For clinicians, they represent the ideal environment: multiple specialists, shared context, and time to debate the gray areas that guidelines can’t fully capture. However, during a busy afternoon in the clinic, the plans developed in tumor boards often prove less straightforward to implement. In this episode of Oncology Unfiltered, Melissa Cutrona, MS, and Matthew Hadfield, DO, OncData Editor in Chief, unpack why tumor boards are so valuable, where they fall short, and how to bridge the gap between a coordinated plan and the reality of care delivery on a busy clinic day.

Check out the full article at: https://oncdata.com/oncology-unfiltered-the-real-world-vs-the-trial-patient

Every oncologist knows the moment well: you're reviewing treatment options with a patient, guidelines in hand, when you realize the person sitting across from you wouldn't have qualified for the pivotal trial that established your recommended therapy. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, speaks with Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, about one of oncology's most persistent challenges—the widening gap between carefully curated trial populations and the complex, real-world patients who enter clinics daily.

Read the full article at: https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne

Artificial intelligence (AI) continues to generate excitement across oncology, but its real-world clinical impact remains uneven. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, a Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shares his American Association for Cancer Research (AACR) presentation on AI-driven pathological subtyping in pancreatic cancer and highlights a critical shift: moving AI from theoretical promise to practical application.

Think PFIC is only a pediatric disease? Think again.

Progressive Familial Intrahepatic Cholestasis (PFIC) was long considered a condition exclusive to children. However, breakthroughs in genomic sequencing are revealing a hidden population: adults with "unexplained" cholestasis who are actually living with undiagnosed PFIC variants. Early identification is the difference between manageable care and irreversible liver damage.

In this interview episode Dr. Aparna Goel, Stanford School of Medicine, and Dr. Laura Bull, UC San Francisco, break down the adult phenotype of PFIC and how clinicians can close the diagnostic gap.

What You'll Hear In This Episode:

The Adult Phenotype: Why adult cases often present as "indolent" or mild compared to the severe jaundice seen in infants.

Diagnostic Red Flags: When to move beyond standard autoimmune panels and look for genetic markers.

Genetic Testing 101: A comparison of targeted gene panels vs. whole exome sequencing for the most efficient diagnosis.

The Power of a Name: How a specific PFIC diagnosis changes everything—from family counseling to starting life-altering IBAT inhibitors.

💡 Earn 1.5 Free CME/AAPA Credits

👉 Join the Escape Room: i3health.com/pfic